BPC-157 alternatives.

5 compounds compared to BPC-157, ranked by published evidence tier and regulatory status, not by what's marketed hardest.

Why people look for an alternative

BPC-157 alternatives searches come from two places: people who cannot source it reliably, and people who read the evidence and want something better supported. Both are reasonable. Nearly all of its reputation rests on animal experiments, it is not approved by the FDA or other major regulators for any indication, and its compounding status has whipsawed, placed in Category 2 of the 503A bulk-substances review in 2023 citing significant safety questions, with reporting in 2026 indicating later removal from that list amid renewed review. Removal is not approval. The hard part of this answer: no compound with a comparable tissue-repair mechanism has better human evidence, so the list below trades sideways.

What you're comparing against
BPC-157
D tier · 39/100Research / preclinical

BPC-157 (sometimes written PL 14736 or "Body Protection Compound 157") is a synthetic pentadecapeptide, a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419 Da).

Ranked by evidence · strongest first
  1. 01
    Thymosin β-4
    D tierResearch / preclinical

    Acts through the angiogenesis and tissue repair pathway, like BPC-157. Research / preclinical.

  2. 02
    TB-500
    F tierResearch / preclinical
    thymosin β4 fragment

    Acts through the angiogenesis and tissue repair pathway, like BPC-157. Research / preclinical.

  3. 03
    Pentosan Polysulfate
    B tierFDA-approved
    Elmiron

    Same category: healing & recovery. FDA-approved.

  4. 04
    Larazotide
    C tierIn human trials
    AT-1001 · larazotide acetate

    Same category: healing & recovery. In human trials.

  5. 05
    B7-33
    F tierResearch / preclinical
    single-chain relaxin analog

    Same category: healing & recovery. Research / preclinical.

How this list is built

An “alternative” here means a compound that shares BPC-157's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.

Comparing options with your provider?

PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page
Compounds